Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616303 · ClinicalTrials.gov registry record · Phase 2
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
A Phase 2 study of Ovarian Neoplasms, sponsored by Quest PharmaTech.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 2
- Study locations
NCT01616303 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Quest PharmaTech. The registered enrollment target is 97 participants, below the 365-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01616303, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Quest PharmaTech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL oregovomab
Study Locations (2)
Connecticut
- University of Connecticut Health Center - Farmington
Indiana
- Northern Indiana Cancer Research Consortium - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2012-06-15 |
| Est. Completion | 2018-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01616303
The ClinicalTrials.gov registry entry for NCT01616303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 365-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (73% lower). The listed sponsor is Quest PharmaTech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01616303 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Indiana.
Frequently Asked Questions
What is clinical trial NCT01616303 about?
NCT01616303 is a clinical study titled "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer". This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclita...
What is the current status of trial NCT01616303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2012-06-15. Estimated completion is 2018-10-12.
What conditions does trial NCT01616303 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
What interventions are being tested in trial NCT01616303?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), oregovomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01616303?
This trial is sponsored by Quest PharmaTech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01616303 being conducted?
This trial has 2 study locations across Connecticut, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.